Biomarin Pharmaceutical (BMRN) Interest Expenses (2009 - 2026)

Biomarin Pharmaceutical's Interest Expenses history runs 18 years deep, the most recent figure standing at $17.4 million for Q1 2026.

• Quarterly Interest Expenses rose 508.0% year-over-year to $17.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.4 million (up 37.66% YoY) and the FY2025 annual result came in at $181.7 million, up 43.89% from the prior year.
• Interest Expenses was $17.4 million for Q1 2026 at Biomarin Pharmaceutical, up from $7.3 million in the prior quarter.
• Across five years, Interest Expenses topped out at $21.5 million in Q4 2023 and bottomed at -$2.1 million in Q4 2022.
• A 5-year average of $5.3 million and a median of $3.8 million in 2023 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2022 — Interest Expenses plunged 110.26% — and 2023, when it jumped 1140.38%.
• Biomarin Pharmaceutical's Interest Expenses stood at -$2.1 million in 2022, then soared by 1140.38% to $21.5 million in 2023, then slumped by 85.81% to $3.0 million in 2024, then surged by 140.62% to $7.3 million in 2025, then surged by 137.57% to $17.4 million in 2026.
• Business Quant data shows BMRN's Interest Expenses at $17.4 million in Q1 2026, $7.3 million in Q4 2025, and $2.6 million in Q3 2025.